ClinicalTrials.gg
CompletedNCT03680287Updated Oct 21, 2026Results posted

Effects of Sleep Disruption on Drug Response

A Phase 2 interventional study of Within-Subject test of blinded study medication in Low Back Pain, Recurrent and Healthy, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Basic science

How we know

Updated Oct 21, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Low Back Pain by Johns Hopkins University — 3 open to participants now, 3 under way, none of them phase 3. Low Back Pain · Johns Hopkins University.

Enrollment
9th of 16
109 · median 117
Started
2019
with 1 other
Phase 2
2 of 17
none open now
Registered
10th of 17
by date

Among the 17 studies in Low Back Pain by Johns Hopkins University, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 10th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

3 of the 17 studies in Low Back Pain by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Low Back Pain by Johns Hopkins University, or all of them as a file.
02

Study summary

The central scientific premise of the proposed study is that sleep disruption (SD) will influence individuals' subjective response to blinded medication administration. The investigators further believe these responses will vary among patients who have chronic low back pain (CLBP) vs. healthy controls, and that sex will moderate effects.

The proposed study evaluates whether CLBP patients' subjective responses to study medication administration are altered by SD. The investigators focus on two outcome domains: abuse liability (i.e., drug liking and valuation) and response to pain testing.

The investigators propose a mixed between-within randomized crossover human-laboratory experiment that investigates placebo-controlled effects of study medication on 1) abuse liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked standardized pain measures, after one night of uninterrupted sleep (US) and again after one night of SD. The investigators will recruit both CLBP patients(*) and healthy controls (N = 60).

(*) We originally aimed to accrue 60 subjects with CLBP. However, we have been granted approval by the National Institute on Drug Abuse (NIDA) to reduce expectations for the target N for the CLBP cohort. We are no longer expected to recruit N=60 CLBP participants; this is a COVID-19 modification, and we are not required to re-do a power analysis.

03

Conditions studied

  • Low Back Pain, Recurrent
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria:

  • 18-60 years old
  • Less than 2 servings/day of caffeinated beverages and willing to discontinue 3 days prior to admission.

CLBP-Specific Inclusion Criteria:

  • Have a physician-confirmed diagnosis of CLBP
  • Report chronic low back pain.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  • >40
  • Significant medical or psychiatric morbidity within 6 months or lifetime history of bipolar disorder, psychotic disorder, seizure disorder
  • Lifetime history of opioid use disorder
  • abnormal complete blood count or comprehensive metabolic profile
  • Any medical condition (status asthmaticus; ; reduced respiratory function; hypotension; hypertension; impairment of hepatic, pulmonary or renal functions; myxedema or hyperthyroidism; adrenocortical insufficiency; gastrointestinal obstruction; gall bladder disease; acute alcoholism; history of convulsive disorders; history of head injury)
  • Current use of stimulants, opioids, benzodiazepines or other Central Nervous System (CNS) depressant
  • Positive toxicology screen for opioids, stimulants, or recreational drugs
  • Pregnancy or lactation
  • Significant preadmission psychological distress.

Healthy Control and CLBP-Specific Exclusion Criteria:

  • Report current medical/psychiatry history
  • Report acute painful injury (within 3 months)
  • Have a diagnosed chronic pain disorder.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Active comparator
    Uninterrupted Sleep

    Participants will be permitted to sleep without interruption for 8 hours.

    Drug: Within-Subject test of blinded study medication

  • Experimental
    Sleep Disruption

    Participants will be repeatedly awakened throughout the night according to a standardized protocol.

    Drug: Within-Subject test of blinded study medication

Interventions

  • DrugWithin-Subject test of blinded study medication

    On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. Participants receive up to four injections, starting with placebo (saline). This is followed by ascending doses of Hydromorphone (0.14, 0.28, and 0.56mg/70kg). This study uses a within-subject design, such that participants serve as participants' own control.

06

What researchers measure

Primary outcomes

  1. Drug Liking as Assessed by the Visual Analog Scale

    Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Do you like the drug?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  2. Heat Pain Threshold

    A thermode will gradually increase in temperature until the participant indicates when it "first feels painful". The outcome will be the temperature (degrees Celsius) at which the participant indicates they first feel pain. Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  3. Suprathreshold Tonic Heat Pain

    A painful temperature above threshold will be held tonically for a period of time, after which pain ratings are obtained on a 0-100 numerical rating scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  4. Monetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire

    Participants are presented with an array of choices (in dollar value) which they will compare to the option of receiving study drug. They will decide for each choice whether they would take the money (at that value) or the drug they received in the session. The outcome will be the "crossover point", which is the mean of the last price that the participant selected "drug" and the first price at which the participant selected "money". Values reported represent those from a single administration following the drug administration assessment period.

    Time frame: up to 420 minute post-medication administration

Secondary outcomes

  1. Good Drug Effects as Assessed by the Visual Analog Scale

    Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any good effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  2. Bad Drug Effects as Assessed by the Visual Analog Scale

    Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any bad effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  3. Level of "Highness" as Assessed by Visual Analog Scale

    Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "How high are you?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  4. Feeling of Sickness as Assessed by Visual Analog Scale

    Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does this drug make you feel sick?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

  5. Clinical Pain

    This will be rated on a 0-100 Numerical Rating Scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

    Time frame: up to 420 minute post-medication administration

07

Results

Posted Oct 21, 2026

Participant flow

Recruitment was conducted through print and media advertisements in the greater Baltimore metropolitan area, MyChart messages through the Johns Hopkins MyChart recruitment service, and contacting participants from previous laboratory studies who had previously agreed to be contacted for future studies. 109 participants were enrolled, 81 were ineligible and were not randomized. 28 participants were randomized.

First Intervention (1 Night)
Participant flow — First Intervention (1 Night)
MilestoneUninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)
Started231211
Placebo231210
Hydromorphone injections (0.14 mg) - 123129
Hydromorphone injections (0.28 mg) - 20396
Hydromorphone injections (0.56 mg/kg) - 30101
Completed231210
Not completed0001
Washout (1 Week)
Participant flow — Washout (1 Week)
MilestoneUninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)
Started231110
Completed231110
Not completed0000
Intervention 2 (1 Night)
Participant flow — Intervention 2 (1 Night)
MilestoneUninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)
Started23118
Placebo23118
Hydromorphone injections (0.14 mg) - 123118
Hydromorphone injections (0.28 mg) - 20385
Hydromorphone injections (0.56 mg/kg) - 30101
Completed23118
Not completed0000

Outcome measures

PrimaryDrug Liking as Assessed by the Visual Analog Scale

Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Do you like the drug?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Drug Liking as Assessed by the Visual Analog Scale
score on a scaleUninterrupted Sleep/Healthy ControlSleep Disruption/Healthy ControlUninterrupted Sleep/CLBPSleep Disruption/CLBP
Drug Liking as Assessed by the Visual Analog Scale10.2 ± 20.55.6 ± 14.022.2 ± 29.116.4 ± 23.0
PrimaryHeat Pain Threshold

A thermode will gradually increase in temperature until the participant indicates when it "first feels painful". The outcome will be the temperature (degrees Celsius) at which the participant indicates they first feel pain. Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · degrees celsius
Heat Pain Threshold
degrees celsiusUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Heat Pain Threshold42.6 ± 3.241.7 ± 3.542.1 ± 2.841.4 ± 3.2
PrimarySuprathreshold Tonic Heat Pain

A painful temperature above threshold will be held tonically for a period of time, after which pain ratings are obtained on a 0-100 numerical rating scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Suprathreshold Tonic Heat Pain
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Suprathreshold Tonic Heat Pain46.0 ± 23.050.0 ± 26.060.0 ± 28.063.0 ± 29.0
PrimaryMonetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire

Participants are presented with an array of choices (in dollar value) which they will compare to the option of receiving study drug. They will decide for each choice whether they would take the money (at that value) or the drug they received in the session. The outcome will be the "crossover point", which is the mean of the last price that the participant selected "drug" and the first price at which the participant selected "money". Values reported represent those from a single administration following the drug administration assessment period.

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · US dollars
Monetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire
US dollarsUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Monetary Valuation of Drug as Assessed by the Drug vs. Money Multiple Choice Questionnaire6.1 ± 7.13.4 ± 6.62.8 ± 4.98.5 ± 5.7
SecondaryGood Drug Effects as Assessed by the Visual Analog Scale

Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any good effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Good Drug Effects as Assessed by the Visual Analog Scale
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Good Drug Effects as Assessed by the Visual Analog Scale8.4 ± 17.34.2 ± 11.020.5 ± 27.611.6 ± 21.0
SecondaryBad Drug Effects as Assessed by the Visual Analog Scale

Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does the drug have any bad effects?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Bad Drug Effects as Assessed by the Visual Analog Scale
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Bad Drug Effects as Assessed by the Visual Analog Scale2.9 ± 8.48.4 ± 23.07.9 ± 16.17.9 ± 6.0
SecondaryLevel of "Highness" as Assessed by Visual Analog Scale

Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "How high are you?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Level of "Highness" as Assessed by Visual Analog Scale
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Level of "Highness" as Assessed by Visual Analog Scale5.8 ± 10.97.4 ± 21.010.2 ± 17.64.9 ± 11.0
SecondaryFeeling of Sickness as Assessed by Visual Analog Scale

Visual Analog Scale (0-100), where 0=None and 100 = Extremely , in response to the question, "Does this drug make you feel sick?" Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Feeling of Sickness as Assessed by Visual Analog Scale
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Feeling of Sickness as Assessed by Visual Analog Scale2.4 ± 8.47.1 ± 22.01.8 ± 6.54.7 ± 10.0
SecondaryClinical Pain

This will be rated on a 0-100 Numerical Rating Scale, where 0 = "No Pain" and 100 = "Worst Pain Imaginable." Values reported represent average values across time points in the drug administration assessment period (up to 420 minutes).

Time frame:
up to 420 minute post-medication administration
Reported as:
Mean · score on a scale
Clinical Pain
score on a scaleUninterrupted Sleep/Healthy ControlsSleep Disruption/Healthy ControlsUninterrupted Sleep/CLBPSleep Disruption/CLBP
Clinical Pain3.0 ± 7.71.1 ± 3.411.0 ± 15.018.0 ± 35.0

Adverse events

Collected over AEs were assessed at the Opioid challenge session (Visit 2), and again after each subsequent visit (Visit 3 and Visit 4), up to 9 days. This comprises all visits in which drug administration and/or sleep manipulations occurred.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
(Healthy Controls): Uninterrupted Sleep0/28 (0%)0/28 (0%)3/28 (10.7%)
(Healthy Controls): Sleep Disruption0/28 (0%)0/28 (0%)2/28 (7.1%)
(CLBP): Uninterrupted Sleep0/28 (0%)0/28 (0%)1/28 (3.6%)
(CLBP):Sleep Disruption0/28 (0%)0/28 (0%)1/28 (3.6%)
Most frequent other events
Most frequent other events
Event(Healthy Controls): Uninterrupted Sleep(Healthy Controls): Sleep Disruption(CLBP): Uninterrupted Sleep(CLBP):Sleep Disruption
VomitingGastrointestinal disorders1/281/280/280/28
Hip PainMusculoskeletal and connective tissue disorders1/280/280/280/28
NauseaGastrointestinal disorders1/281/280/281/28
ShinglesInfections and infestations0/280/281/280/28

Baseline characteristics

Age, Continuous
Age, Continuous(age in years)Uninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)Total
Mean32 ± 1537 ± 1040 ± 1137 ± 1137.82 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)Uninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)Total
Female118818
Male124310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Uninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)Total
Hispanic or Latino01012
Not Hispanic or Latino22121026
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Uninterrupted Sleep First, Then Sleep Disruption (CLBP)Sleep Disruption First, Then Uninterrupted Sleep (CLBP)Uninterrupted Sleep First, Then Sleep Disruption (Healthy Controls)Sleep Disruption First, Then Uninterrupted Sleep (Healthy Controls)Total
American Indian or Alaska Native01001
Asian10124
Native Hawaiian or Other Pacific Islander00000
Black or African American00336
White127515
More than one race00101
Unknown or Not Reported00011
08

Study locations

1 site
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21224, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Apr 2025, 66 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 33 phase 2 interventional studies under Low Back Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2018
First posted
Sep 21, 2018
StartActual
Oct 7, 2019
Primary completionActual
Apr 29, 2025
CompletionActual
Apr 29, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Primary outcomes
2 edited, 2 description edited
What changed in the outcomes
  • EditedDrug Liking as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
  • EditedMonetary Valuation of Drug as assessedAssessed by the Drug vs. Money Multiple Choice QuestionnaireTime frame: up to 420 minute post-medication administration
  • DescriptionHeat Pain Threshold: how it is measured was reworded
  • DescriptionSuprathreshold Tonic Heat Pain: how it is measured was reworded
Oct 21, 2026
Documents
Secondary outcomes
4 edited, 1 description edited
What changed in the outcomes
  • EditedGood Drug Effects as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
  • EditedBad Drug Effects as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
  • EditedLevel of "Highness" as assessedAssessed by Visual Analog ScaleTime frame: up to 420 minute post-medication administration
  • EditedFeeling of Sickness as assessedAssessed by Visual Analog ScaleTime frame: up to 420 minute post-medication administration
  • DescriptionClinical Pain: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Primary outcomes 2 edited, 2 description edited
    What changed in the outcomes
    • EditedDrug Liking as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
    • EditedMonetary Valuation of Drug as assessedAssessed by the Drug vs. Money Multiple Choice QuestionnaireTime frame: up to 420 minute post-medication administration
    • DescriptionHeat Pain Threshold: how it is measured was reworded
    • DescriptionSuprathreshold Tonic Heat Pain: how it is measured was reworded
    Secondary outcomes 4 edited, 1 description edited
    What changed in the outcomes
    • EditedGood Drug Effects as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
    • EditedBad Drug Effects as assessedAssessed by the Visual Analog ScaleTime frame: up to 420 minute post-medication administration
    • EditedLevel of "Highness" as assessedAssessed by Visual Analog ScaleTime frame: up to 420 minute post-medication administration
    • EditedFeeling of Sickness as assessedAssessed by Visual Analog ScaleTime frame: up to 420 minute post-medication administration
    • DescriptionClinical Pain: how it is measured was reworded
    + 3 other changes: index terms, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03680287
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Oct 7, 2019
Primary completion
Apr 29, 2025
Completion
Apr 29, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Michael T. Smith, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion